Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
A Multi-Center, Randomized, Phase 3 Study of Adjuvant Oncophage® Versus Observation in Patients With High Risk After Surgical Treatment for Renal Cell Carcinoma
Sponsor: Agenus Inc.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Agenus Inc.
- Gliosarcoma · Phase PHASE2 · May 2023
- Advanced Solid Tumor · Phase PHASE1 · Sep 2021
- Advanced Cancer · Phase PHASE1 · Dec 2019
- NSCLC Stage IV · Phase PHASE2 · Mar 2019
- Renal Cell Carcinoma · Phase PHASE2 · Jun 2012
More terminations from Agenus Inc.
A PHASE3 clinical study on Kidney Cancer and Renal Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Agenus Inc. and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
May 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agenus Inc.
For direct contact, visit the study record on ClinicalTrials.gov .